108 related articles for article (PubMed ID: 26219385)
1. Exploring resistance mechanisms of HCV NS3/4A protease mutations to MK5172: insight from molecular dynamics simulations and free energy calculations.
Guan Y; Sun H; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2015 Sep; 11(9):2568-78. PubMed ID: 26219385
[TBL] [Abstract][Full Text] [Related]
2. Molecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435.
Xue W; Pan D; Yang Y; Liu H; Yao X
Antiviral Res; 2012 Jan; 93(1):126-37. PubMed ID: 22127068
[TBL] [Abstract][Full Text] [Related]
3. Understanding the structural and energetic basis of inhibitor and substrate bound to the full-length NS3/4A: insights from molecular dynamics simulation, binding free energy calculation and network analysis.
Xue W; Wang M; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Oct; 8(10):2753-65. PubMed ID: 22833015
[TBL] [Abstract][Full Text] [Related]
4. Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Wang H; Geng L; Chen BZ; Ji M
Biochem Cell Biol; 2014 Oct; 92(5):357-69. PubMed ID: 25178998
[TBL] [Abstract][Full Text] [Related]
5. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Xue W; Ban Y; Liu H; Yao X
J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
[TBL] [Abstract][Full Text] [Related]
6. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
[TBL] [Abstract][Full Text] [Related]
7. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
[TBL] [Abstract][Full Text] [Related]
8. Understanding the drug resistance mechanism of hepatitis C virus NS3/4A to ITMN-191 due to R155K, A156V, D168A/E mutations: a computational study.
Pan D; Xue W; Zhang W; Liu H; Yao X
Biochim Biophys Acta; 2012 Oct; 1820(10):1526-34. PubMed ID: 22698669
[TBL] [Abstract][Full Text] [Related]
9. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
Palanisamy N; Lennerstrand J
Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
[TBL] [Abstract][Full Text] [Related]
10. Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease.
Nagpal N; Goyal S; Wahi D; Jain R; Jamal S; Singh A; Rana P; Grover A
Gene; 2015 Oct; 570(1):115-21. PubMed ID: 26055089
[TBL] [Abstract][Full Text] [Related]
11. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
12. The competitive binding between inhibitors and substrates of HCV NS3/4A protease: a general mechanism of drug resistance.
Guan Y; Sun H; Li Y; Pan P; Li D; Hou T
Antiviral Res; 2014 Mar; 103():60-70. PubMed ID: 24462696
[TBL] [Abstract][Full Text] [Related]
13. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
14. [Molecular recognition mechanism and motion of HCV NS3/4A protease with Faldaprevir analogue].
Liang L; Hu J; Du W; Zuo K; Liu W; Gou X
Sheng Wu Gong Cheng Xue Bao; 2016 May; 32(5):669-682. PubMed ID: 29019204
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the mechanisms of Sofosbuvir resistance in HCV NS3/4A protease: Structural and molecular simulation-based insights.
Shahab M; Khan A; Khan SA; Zheng G
Int J Biol Macromol; 2024 May; 267(Pt 2):131629. PubMed ID: 38631585
[TBL] [Abstract][Full Text] [Related]
16. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
[TBL] [Abstract][Full Text] [Related]
17. Computational study on the drug resistance mechanism of HCV NS3 protease to BMS-605339.
Wang H; Guo C; Chen BZ; Ji M
Biotechnol Appl Biochem; 2017 Mar; 64(2):153-164. PubMed ID: 26790544
[TBL] [Abstract][Full Text] [Related]
18. Molecular docking investigation of the binding interactions of macrocyclic inhibitors with HCV NS3 protease and its mutants (R155K, D168A and A156V).
Ezat AA; El-Bialy NS; Mostafa HI; Ibrahim MA
Protein J; 2014 Feb; 33(1):32-47. PubMed ID: 24374429
[TBL] [Abstract][Full Text] [Related]
19. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus.
Welsch C; Domingues FS; Susser S; Antes I; Hartmann C; Mayr G; Schlicker A; Sarrazin C; Albrecht M; Zeuzem S; Lengauer T
Genome Biol; 2008 Jan; 9(1):R16. PubMed ID: 18215275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
